vs
PUMA BIOTECHNOLOGY, INC.（PBYI）与TruBridge, Inc.（TBRG）财务数据对比。点击上方公司名可切换其他公司
TruBridge, Inc.的季度营收约是PUMA BIOTECHNOLOGY, INC.的1.2倍（$87.8M vs $75.5M），PUMA BIOTECHNOLOGY, INC.同比增速更快（27.7% vs 0.0%），PUMA BIOTECHNOLOGY, INC.自由现金流更多（$14.4M vs $8.4M），过去两年PUMA BIOTECHNOLOGY, INC.的营收复合增速更高（31.3% vs 2.2%）
彪马生物技术是一家公开上市的生物制药企业，总部位于美国加利福尼亚州洛杉矶，专注于创新药物研发相关业务，在生物制药领域开展研发与商业化运营。
TruBridge, Inc.主要为美国各地的乡村及社区医疗机构提供端到端的营收周期管理、医疗信息技术解决方案及相关行政支持服务，帮助客户优化运营效率、提升财务表现。
PBYI vs TBRG — 直观对比
营收规模更大
TBRG
是对方的1.2倍
$75.5M
营收增速更快
PBYI
高出27.7%
0.0%
自由现金流更多
PBYI
多$6.0M
$8.4M
两年增速更快
PBYI
近两年复合增速
2.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $75.5M | $87.8M |
| 净利润 | — | $-4.3M |
| 毛利率 | 69.3% | 54.3% |
| 营业利润率 | 22.7% | 5.7% |
| 净利率 | — | -4.9% |
| 营收同比 | 27.7% | 0.0% |
| 净利润同比 | — | 22.8% |
| 每股收益（稀释后） | $0.26 | $-0.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PBYITBRG
| Q4 25 | $75.5M | $87.8M | ||
| Q3 25 | $54.5M | $86.1M | ||
| Q2 25 | $52.4M | $85.7M | ||
| Q1 25 | $46.0M | $87.2M | ||
| Q4 24 | $59.1M | $87.8M | ||
| Q3 24 | $80.5M | $84.7M | ||
| Q2 24 | $47.1M | $85.6M | ||
| Q1 24 | $43.8M | $84.1M |
净利润PBYITBRG
| Q4 25 | — | $-4.3M | ||
| Q3 25 | $8.8M | $5.6M | ||
| Q2 25 | $5.9M | $2.6M | ||
| Q1 25 | $3.0M | $459.0K | ||
| Q4 24 | — | $-5.6M | ||
| Q3 24 | $20.3M | $-9.1M | ||
| Q2 24 | $-4.5M | $-4.4M | ||
| Q1 24 | $-4.8M | $-1.9M |
毛利率PBYITBRG
| Q4 25 | 69.3% | 54.3% | ||
| Q3 25 | 77.7% | 51.2% | ||
| Q2 25 | 76.5% | 51.9% | ||
| Q1 25 | 77.1% | 54.7% | ||
| Q4 24 | 76.4% | 52.8% | ||
| Q3 24 | 63.9% | 50.0% | ||
| Q2 24 | 77.4% | 49.4% | ||
| Q1 24 | 75.5% | 50.4% |
营业利润率PBYITBRG
| Q4 25 | 22.7% | 5.7% | ||
| Q3 25 | 17.6% | 4.7% | ||
| Q2 25 | 12.7% | 4.2% | ||
| Q1 25 | 8.7% | 9.4% | ||
| Q4 24 | 22.6% | 7.2% | ||
| Q3 24 | 27.4% | 3.3% | ||
| Q2 24 | -4.6% | -2.5% | ||
| Q1 24 | -5.3% | -0.7% |
净利率PBYITBRG
| Q4 25 | — | -4.9% | ||
| Q3 25 | 16.2% | 6.5% | ||
| Q2 25 | 11.2% | 3.0% | ||
| Q1 25 | 6.5% | 0.5% | ||
| Q4 24 | — | -6.3% | ||
| Q3 24 | 25.2% | -10.8% | ||
| Q2 24 | -9.6% | -5.1% | ||
| Q1 24 | -11.0% | -2.2% |
每股收益（稀释后）PBYITBRG
| Q4 25 | $0.26 | $-0.28 | ||
| Q3 25 | $0.17 | $0.37 | ||
| Q2 25 | $0.12 | $0.17 | ||
| Q1 25 | $0.06 | $0.03 | ||
| Q4 24 | $0.40 | $-0.38 | ||
| Q3 24 | $0.41 | $-0.61 | ||
| Q2 24 | $-0.09 | $-0.29 | ||
| Q1 24 | $-0.10 | $-0.13 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $97.5M | $24.9M |
| 总债务越低越好 | $22.7M | $164.6M |
| 股东权益账面价值 | $130.3M | $178.0M |
| 总资产 | $216.3M | $402.5M |
| 负债/权益比越低杠杆越低 | 0.17× | 0.93× |
8季度趋势，按日历期对齐
现金及短期投资PBYITBRG
| Q4 25 | $97.5M | $24.9M | ||
| Q3 25 | $94.4M | $19.9M | ||
| Q2 25 | $96.0M | $12.3M | ||
| Q1 25 | $93.2M | $10.1M | ||
| Q4 24 | $101.0M | $12.3M | ||
| Q3 24 | $96.7M | $8.6M | ||
| Q2 24 | $96.8M | $7.7M | ||
| Q1 24 | $107.2M | $4.1M |
总债务PBYITBRG
| Q4 25 | $22.7M | $164.6M | ||
| Q3 25 | $34.0M | $164.3M | ||
| Q2 25 | $45.3M | $166.1M | ||
| Q1 25 | $56.7M | $167.8M | ||
| Q4 24 | $68.0M | $171.6M | ||
| Q3 24 | $79.3M | $176.3M | ||
| Q2 24 | $90.7M | $180.0M | ||
| Q1 24 | $102.0M | $184.8M |
股东权益PBYITBRG
| Q4 25 | $130.3M | $178.0M | ||
| Q3 25 | $115.3M | $180.4M | ||
| Q2 25 | $104.7M | $173.2M | ||
| Q1 25 | $97.1M | $168.5M | ||
| Q4 24 | $92.1M | $167.1M | ||
| Q3 24 | $71.1M | $172.0M | ||
| Q2 24 | $48.5M | $179.8M | ||
| Q1 24 | $51.0M | $182.7M |
总资产PBYITBRG
| Q4 25 | $216.3M | $402.5M | ||
| Q3 25 | $202.9M | $399.4M | ||
| Q2 25 | $194.9M | $390.2M | ||
| Q1 25 | $196.2M | $388.8M | ||
| Q4 24 | $213.3M | $395.8M | ||
| Q3 24 | $220.7M | $401.5M | ||
| Q2 24 | $205.0M | $412.3M | ||
| Q1 24 | $214.1M | $416.4M |
负债/权益比PBYITBRG
| Q4 25 | 0.17× | 0.93× | ||
| Q3 25 | 0.30× | 0.91× | ||
| Q2 25 | 0.43× | 0.96× | ||
| Q1 25 | 0.58× | 1.00× | ||
| Q4 24 | 0.74× | 1.03× | ||
| Q3 24 | 1.12× | 1.02× | ||
| Q2 24 | 1.87× | 1.00× | ||
| Q1 24 | 2.00× | 1.01× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $14.4M | $8.9M |
| 自由现金流经营现金流 - 资本支出 | $14.4M | $8.4M |
| 自由现金流率自由现金流/营收 | 19.1% | 9.5% |
| 资本支出强度资本支出/营收 | 0.0% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $41.7M | $35.5M |
8季度趋势，按日历期对齐
经营现金流PBYITBRG
| Q4 25 | $14.4M | $8.9M | ||
| Q3 25 | $9.7M | $13.6M | ||
| Q2 25 | $14.1M | $8.8M | ||
| Q1 25 | $3.6M | $5.8M | ||
| Q4 24 | $15.6M | $9.3M | ||
| Q3 24 | $11.0M | $10.1M | ||
| Q2 24 | $1.0M | $13.8M | ||
| Q1 24 | $11.2M | $-2.0M |
自由现金流PBYITBRG
| Q4 25 | $14.4M | $8.4M | ||
| Q3 25 | $9.7M | $13.5M | ||
| Q2 25 | $14.1M | $8.2M | ||
| Q1 25 | $3.6M | $5.4M | ||
| Q4 24 | $15.6M | $8.9M | ||
| Q3 24 | $11.0M | $9.1M | ||
| Q2 24 | $1.0M | $13.6M | ||
| Q1 24 | — | $-2.2M |
自由现金流率PBYITBRG
| Q4 25 | 19.1% | 9.5% | ||
| Q3 25 | 17.7% | 15.7% | ||
| Q2 25 | 26.8% | 9.6% | ||
| Q1 25 | 7.7% | 6.2% | ||
| Q4 24 | 26.4% | 10.2% | ||
| Q3 24 | 13.7% | 10.8% | ||
| Q2 24 | 2.1% | 15.9% | ||
| Q1 24 | — | -2.6% |
资本支出强度PBYITBRG
| Q4 25 | 0.0% | 0.5% | ||
| Q3 25 | 0.0% | 0.1% | ||
| Q2 25 | 0.0% | 0.6% | ||
| Q1 25 | 0.1% | 0.4% | ||
| Q4 24 | 0.0% | 0.4% | ||
| Q3 24 | 0.0% | 1.1% | ||
| Q2 24 | 0.0% | 0.2% | ||
| Q1 24 | 0.0% | 0.2% |
现金转化率PBYITBRG
| Q4 25 | — | — | ||
| Q3 25 | 1.10× | 2.43× | ||
| Q2 25 | 2.41× | 3.39× | ||
| Q1 25 | 1.21× | 12.55× | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.54× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PBYI
暂无分部数据
TBRG
| Financial Health Segment | $56.7M | 65% |
| Patient Care Segment | $31.1M | 35% |
